Early intervention and effective therapies are transforming multiple sclerosis management, enhancing patient outcomes, and delaying disability progression.

Aging and shifting hormone levels influence how MS changes over time, and the overlap of these factors during midlife can ...

Findings showed fenebrutinib significantly reduced relapses vs teriflunomide in RMS and was noninferior to ocrelizumab in slowing disability progression in PPMS. Topline data were announced from two ...

Roche’s fenebrutinib shows unprecedented positive phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis ...

The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomideIn a pivotal PPMS study ...

Levels of antibodies targeting the Epstein-Barr virus are not associated with disease activity among multiple sclerosis ...

People with MS of all ages and genders consistently report reduced quality of life relative to the general population, a ...

As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly ...

Popular ideas about inflammation have lost touch with medical reality.

Gain insight on Pfizer’s purchase of Metsera, Roche’s fenebrutinib results, and more in the latest Market Talks covering the ...